Susquehanna International Group’s Aimmune Therapeutics AIMT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-238,307
| Closed | -$8.21M | – | 12114 |
|
|
2020
Q3 | $8.21M | Buy |
238,307
+12,477
| +6% | +$266K | ﹤0.01% | 2428 |
|
|
2020
Q2 | $3.77M | Buy |
225,830
+17,658
| +8% | +$300K | ﹤0.01% | 3420 |
|
|
2020
Q1 | $3M | Sell |
208,172
-17,680
| -8% | -$452K | ﹤0.01% | 3281 |
|
|
2019
Q4 | $7.56M | Buy |
225,852
+40,863
| +22% | +$1.14M | ﹤0.01% | 2425 |
|
|
2019
Q3 | $3.87M | Buy |
184,989
+92,336
| +100% | +$1.89M | ﹤0.01% | 3098 |
|
|
2019
Q2 | $1.93M | Buy |
92,653
+24,119
| +35% | +$497K | ﹤0.01% | 4244 |
|
|
2019
Q1 | $1.53M | Sell |
68,534
-39,161
| -36% | -$922K | ﹤0.01% | 4200 |
|
|
2018
Q4 | $2.58M | Buy |
+107,695
| New | +$2.79M | ﹤0.01% | 3144 |
|
|
2018
Q3 | – | Sell |
-11,470
| Closed | -$324K | – | 10652 |
|
|
2018
Q2 | $308K | Sell |
11,470
-124,801
| -92% | -$3.82M | ﹤0.01% | 7793 |
|
|
2018
Q1 | $4.34M | Buy |
136,271
+120,960
| +790% | +$4.26M | ﹤0.01% | 2722 |
|
|
2017
Q4 | $579K | Sell |
15,311
-37,953
| -71% | -$1.22M | ﹤0.01% | 6372 |
|
|
2017
Q3 | $1.32M | Buy |
+53,264
| New | +$1.15M | ﹤0.01% | 4733 |
|
|
2017
Q1 | – | Sell |
-45,094
| Closed | -$925K | – | 10423 |
|
|
2016
Q4 | $922K | Buy |
+45,094
| New | +$922K | ﹤0.01% | 5707 |
|
|
2016
Q3 | – | Sell |
-19,164
| Closed | -$207K | – | 9319 |
|
|
2016
Q2 | $207K | Buy |
+19,164
| New | +$260K | ﹤0.01% | 7558 |
|
|
2015
Q4 | – | Sell |
-38,373
| Closed | -$972K | – | 10223 |
|
|
2015
Q3 | $972K | Buy |
+38,373
| New | +$897K | ﹤0.01% | 5819 |
|
Susquehanna International Group's AIMT Position: Q4 2020 in Review
Susquehanna International Group sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 238,307 shares — an estimated $8.21M sold.
Susquehanna International Group first reported a position in AIMT in Q3 2015 and held it in 15 quarters. The position peaked at $8.21M in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.
- Susquehanna International Group reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
- Susquehanna International Group sold 238,307 Aimmune Therapeutics shares in Q4 2020, an estimated $8.21M.
- Susquehanna International Group first reported a position in Aimmune Therapeutics in Q3 2015 and held it in 15 quarters.
- Susquehanna International Group's Aimmune Therapeutics position peaked at $8.21M in Q3 2020.
- 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.
Based on Susquehanna International Group's 13F filing for Q4 2020, filed 16 Feb 2021.